Why Your LDL Number Is Misleading You (And What to Look at Instead)

LDL cholesterol (LDL-C) is the number doctors have focused on for 40 years. The problem is that LDL-C measures cholesterol concentration inside particles, not the number of particles. Particle count — measured by ApoB or LDL-P — is a stronger predictor of cardiovascular events. The two can diverge substantially, and that divergence has consequences.

The standard cardiovascular risk conversation goes like this: "Your LDL is 130. That's borderline high. Let's work on your diet and recheck in 6 months."

This conversation is based on a measurement that was adopted in the 1970s when it was the best available proxy for cardiovascular risk. The science has moved considerably since then, but the conversation hasn't kept up.

Here's what's actually going on and why it matters.

The Problem With LDL-C

LDL-C measures the concentration of cholesterol within LDL particles. It's calculated (or in modern labs, directly measured) from a standard blood draw.

The fundamental issue: cholesterol concentration in particles is not the same as number of particles. And it's the particles — not their cholesterol content — that embed in arterial walls and initiate plaque formation.

Think of it this way. LDL-C tells you how much stuff is being transported. What you need to know is how many trucks are on the road.

Two people can have identical LDL-C numbers with dramatically different cardiovascular risk:

• Person A has 800 large LDL particles per nanoliter, each loaded with cholesterol.
• Person B has 1,400 small dense LDL particles per nanoliter, each carrying less cholesterol.

Both might show LDL-C of 120 mg/dL. But Person B has 75% more particles traversing the arterial wall, and small dense LDL is more atherogenic than large fluffy LDL (smaller particles penetrate more easily into arterial walls and are more susceptible to oxidation).

LDL-C catches Person A but misses Person B. ApoB catches both.

LDL-P and ApoB: What They Measure

LDL-P (LDL particle number) is measured via nuclear magnetic resonance (NMR) spectroscopy. It directly counts the number of LDL particles. Higher LDL-P = more atherogenic particles = higher cardiovascular risk.

ApoB (apolipoprotein B) is a protein present on every atherogenic lipoprotein — LDL, VLDL, IDL, and Lp(a). One ApoB per particle means ApoB is also a direct particle count, but for all atherogenic particles, not just LDL.

ApoB is generally considered the more comprehensive marker:

• It captures VLDL and IDL particles in addition to LDL
• It's cheaper and more widely available than NMR/LDL-P
• It's a single number rather than a calculation

Both are superior to LDL-C for cardiovascular risk prediction. ApoB has largely supplanted LDL-P in clinical research as the preferred marker.

The Concordance / Discordance Problem

LDL-C and ApoB are concordant in most people — if one is high, the other is high. The issue is the subset of people where they diverge.

Pattern A (large LDL particles — LDL-C high, ApoB normal) This person has a normal number of LDL particles but each is large and cholesterol-rich. Their LDL-C is high but their actual cardiovascular risk from particle count is lower than LDL-C suggests. They may be put on a statin based on LDL-C when ApoB doesn't indicate elevated risk.

Pattern B (small dense LDL — LDL-C normal, ApoB elevated) This person has many small LDL particles, each carrying less cholesterol. LDL-C looks fine on paper — possibly even "optimal" — but ApoB reveals an elevated particle count and substantially higher cardiovascular risk. This person gets told they're fine when they're not.

Pattern B is common in people with:

• Metabolic syndrome or insulin resistance
• High carbohydrate intake
• Elevated triglycerides with relatively normal LDL-C
• Type 2 diabetes or prediabetes

This is the population that's most likely to be missed by standard lipid panels — and it's a large population.

The Research

Several large studies have established ApoB as a superior cardiovascular risk predictor:

• A 2012 analysis of over 300,000 participants in JAMA found non-HDL cholesterol and ApoB superior to LDL-C for predicting first cardiovascular events.
• The INTERHEART study (26 countries, 15,000+ myocardial infarction cases) found the ApoB/ApoA-I ratio was the strongest lipid predictor of acute MI of any lipid marker examined.
• Multiple prospective cohort studies have found ApoB to predict cardiovascular events even after controlling for LDL-C — meaning it provides information beyond what LDL-C captures.

Lp(a): The Hidden Third Variable

Lp(a) — lipoprotein(a) — is an LDL-like particle with an additional protein (apo(a)) attached to it. It's highly atherogenic and is almost entirely genetically determined.

Unlike LDL-C or ApoB, Lp(a) is not meaningfully modifiable by diet or exercise. Its significance is that it adds to atherogenic particle burden (and is counted in ApoB) and has additional prothrombotic effects.

Get Lp(a) tested once. If it's elevated (above 30 mg/dL, or above 75 nmol/L depending on the unit), your cardiovascular risk is higher than standard lipid panels suggest, and your ApoB target should be lower.

What to Do With This Information

1. Get ApoB on your next blood draw. Ask your doctor or order it directly through a lab service. It costs $15–30 out of pocket. For a complete guide on what to add to your standard panel, see how to read your Quest Diagnostics results for longevity.

2. Get Lp(a) tested at least once. If you've never been tested, add it to your next panel. It doesn't change significantly over time, so once is usually sufficient.

3. Interpret LDL-C in context. If LDL-C is elevated but ApoB is optimal (below 80 mg/dL), the particle count concern is lower. If LDL-C is normal but ApoB is elevated, you have a real cardiovascular risk issue that the standard number missed.

4. Talk to a physician who understands particle-based risk. Not all physicians are up to date on this. If your doctor dismisses ApoB as unnecessary, consider seeking a second opinion from a physician with a longevity or preventive cardiology focus.

FAQ

If ApoB is better, why don't doctors routinely test it?

Inertia and guideline lag. Most clinical guidelines were written around LDL-C because it was the marker used in the statin trials. ApoB testing has become more accessible and cheaper, and newer guidelines (including European cardiology guidelines) now recommend it. The US has been slower to update.

My LDL has been high for years but my ApoB is fine. Should I worry?

ApoB in the optimal range (below 60–80 mg/dL) with elevated LDL-C is likely Pattern A — large fluffy LDL particles with normal particle count. The risk is lower than LDL-C alone would suggest. Continue monitoring, optimize lifestyle factors, and discuss with your physician.

Does a low-carb diet raise LDL-C without raising ApoB?

In some people, yes. Low-carb diets with high saturated fat intake can raise LDL-C (Pattern A) without raising ApoB or particle count. For these individuals, the cardiovascular risk increase may be less than the LDL-C number implies. However, some people on low-carb diets show genuine ApoB elevation — which is a real concern. Test both to know.